2024
Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant
Clure C, Sheeder J, Lazorwitz A. Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant. Contraception 2024, 135: 110442. PMID: 38552822, DOI: 10.1016/j.contraception.2024.110442.Peer-Reviewed Original ResearchEtonogestrel contraceptive implantContraceptive implantsMedian body mass indexMedian pain scoreBody mass indexTime pointsBleeding side effectsEtonogestrel implantImplant placementReproductive-age femalesENG implantSite painPain scoresMedian ageInsertion siteEtonogestrelMass indexPilot studyPatient populationInferior edgeSide effectsPharmacokineticsImplantationWeeksSerum
2023
Herbal Supplement Use Among Adolescent and Young Adult Women in a Family Planning Clinic
Friedman J, Sheeder J, Polotsky A, Lazorwitz A. Herbal Supplement Use Among Adolescent and Young Adult Women in a Family Planning Clinic. Journal Of Pediatric And Adolescent Gynecology 2023, 37: 323-329. PMID: 38061680, DOI: 10.1016/j.jpag.2023.11.012.Peer-Reviewed Original ResearchSupplement-drug interactionsYoung adult womenSupplement useHerbal medicineAdult womenGeneral health care providersCommon herbal supplementsCytochrome P450 enzyme inhibitionHormonal contraceptive therapyHerbal medicine useBaseline demographic characteristicsHerbal supplement useTitle X clinicsFamily Planning ClinicCurrent contraceptive methodHealth care providersCross-sectional surveyContraceptive therapyMenstrual irregularitiesCaffeine clearanceMedian ageMedicine usePlanning ClinicInteraction checkerGeneral healthThe effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study
Lazorwitz A, Sheeder J, Teal S. The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study. Contraception 2023, 123: 110035. PMID: 36997081, PMCID: PMC10461170, DOI: 10.1016/j.contraception.2023.110035.Peer-Reviewed Original ResearchConceptsContraceptive implant usersSerum etonogestrel concentrationsStrong CYP3A inducersENG implant usersEtonogestrel concentrationsMedian ageImplant usersCYP3A inducersP4 concentrationsMedian body mass indexSerum E2 concentrationsBody mass indexSignificant decreaseParticipants' median ageSuppression of ovulationSerum P4 concentrationsEffect of rifampinDrug-drug interactionsLiquid chromatography-mass spectrometry assayOnly short exposuresWilcoxon signed-rank testBaseline E2Rifampin 600Rifampin exposureRifampin therapy
2022
Herbal supplement use among reproductive-aged women in an academic infertility practice
Friedman J, Sheeder J, Lazorwitz A, Polotsky A. Herbal supplement use among reproductive-aged women in an academic infertility practice. F&S Reports 2022, 4: 104-111. PMID: 36959959, PMCID: PMC10028423, DOI: 10.1016/j.xfre.2022.12.001.Peer-Reviewed Original ResearchAcademic infertility practiceSupplement-drug interactionsSupplement useHerbal medicineInfertility practiceInteraction checkerInfertility treatmentInfertility therapyHerbal supplementsGeneral health care providersDirect medical supervisionReproductive-aged patientsHerbal supplement useReproductive-aged womenThird of womenHealth care providersCross-sectional survey studyBaseline demographicsPatient demographicsMedian ageEarly pregnancyMedication interactionsHerbal medicationsSupplement interactionsGeneral healthP077Pilot study on a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant
Clure C, Sheeder J, Lazorwitz A. P077Pilot study on a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant. Contraception 2022, 116: 91. DOI: 10.1016/j.contraception.2022.09.101.Peer-Reviewed Original ResearchEtonogestrel contraceptive implantContraceptive implantsENG implantENG levelsSide effectsMedian pain scoreTime pointsReproductive-aged womenScapular insertionPain scoresSite painMedian ageMedian BMIImplant useInferior edgeInsertion siteWeek twoYears of useFirst weekPilot studyImplant usersPharmacokineticsImplantsFirst yearWeeksP079Etonogestrel contraceptive implant users can experience breakthrough ovulation with only two weeks of exposure to a strong cyp3a inducer
Lazorwitz A, Teal S, Sheeder J. P079Etonogestrel contraceptive implant users can experience breakthrough ovulation with only two weeks of exposure to a strong cyp3a inducer. Contraception 2022, 116: 92. DOI: 10.1016/j.contraception.2022.09.103.Peer-Reviewed Original ResearchStrong CYP3A inducersBreakthrough ovulationCYP3A inducersE2 concentrationsP4 concentrationsMedian ageOvulation suppressionImplant usersPg/Baseline serum concentrationsContraceptive implant usersEtonogestrel implant usersSerum E2 concentrationsParticipants' median ageSerum P4 concentrationsENG implant usersDrug-drug interactionsRifampin exposureMedian durationENG implantMedian BMIEndogenous estradiolSerum concentrationsSurrogate biomarkerWeeks of exposureEffect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users
Lazorwitz A, Pena M, Sheeder J, Teal S. Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2022, 139: 579-587. PMID: 35594123, PMCID: PMC9140306, DOI: 10.1097/aog.0000000000004697.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsBody mass indexPg/Median ageImplant usersEnzyme-inducing antiepileptic drugsMedian body mass indexEffects of topiramateMean percent changeParticipants' median ageOvulatory suppressionTopiramate therapyMedian durationTopiramate useEtonogestrel implantsPharmacokinetic interactionsHealthy womenAntiepileptic drugsMass indexNoninferiority studyImplant useMass spectrometry assayPercent change
2019
Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users
Lazorwitz A, Aquilante C, Sheeder J, Guiahi M, Teal S. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users. Contraception 2019, 100: 37-41. PMID: 30980827, PMCID: PMC6589369, DOI: 10.1016/j.contraception.2019.03.045.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersBody mass indexBlack/African American raceEtonogestrel concentrationsAfrican American raceMass indexPatient characteristicsImplant useEtonogestrel levelsImplant usersAmerican raceHispanic/Latina ethnicityMedian body mass indexSerum etonogestrel levelsEtonogestrel contraceptive implantSide effect profileReproductive-age womenCertain patient characteristicsIndividual patient characteristicsMajority of womenNon-significant increaseLatina ethnicityMedian ageSerum concentrations